Titleist Asset Management LLC Has $2.46 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Titleist Asset Management LLC decreased its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 16.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 114,987 shares of the company's stock after selling 23,381 shares during the quarter. Titleist Asset Management LLC's holdings in Kenvue were worth $2,455,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Kiley Juergens Wealth Management LLC lifted its position in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock worth $579,000 after buying an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its position in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock valued at $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC raised its holdings in Kenvue by 1.0% during the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock worth $1,165,000 after acquiring an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators boosted its position in Kenvue by 29.0% during the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock valued at $54,000 after purchasing an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Remove Ads

Kenvue Stock Performance

KVUE stock traded up $0.13 during trading hours on Friday, hitting $22.00. 3,387,462 shares of the stock were exchanged, compared to its average volume of 16,884,395. The company has a 50-day simple moving average of $22.62 and a two-hundred day simple moving average of $22.41. The firm has a market capitalization of $42.04 billion, a P/E ratio of 41.54, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.73%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is currently 154.72%.

Analyst Ratings Changes

Several equities research analysts have recently commented on KVUE shares. Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Redburn Atlantic began coverage on shares of Kenvue in a research report on Thursday. They issued a "neutral" rating and a $23.50 price objective for the company. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $23.96.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.